AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02762058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Mirror Therapy
Description: Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
Study NCT02420886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media
Study NCT03497689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Description: Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
Study NCT01089855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study NCT01860170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study NCT01860170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study NCT01860170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study NCT03645291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Local insect allergen extracts skin test
Description: Every patient received both local and commercial insect allergen extracts but in blinded methods
Study NCT03645291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Local insect allergen extracts skin test
Description: Every patient received both local and commercial insect allergen extracts but in blinded methods
Study NCT00098059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
Study NCT04804852 — intervention group
Intervention type: OTHER
Intervention: sarcopenia assessment
Description: evaluation of sarcopenia by CT san at the C3 vertebrae
Study NCT00759577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Solifenacin
Description: 5mg and 10 mg, oral once daily
Study NCT03177850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study NCT03177850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study NCT02653118 — intervention group
Intervention type: BIOLOGICAL
Intervention: V503
Study NCT02653118 — intervention group
Intervention type: BIOLOGICAL
Intervention: GARDASIL
Study NCT04014335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-FB-LRx
Description: Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
Study NCT00679484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + candesartan cilexetil placebo
Description: Dosage form: tablet; frequency: daily; duration: 24 weeks
Study NCT00679484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil placebo + candesartan cilexetil
Description: Dosage form: tablets; frequency: daily; duration: 24 weeks
Study NCT03562507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
Study NCT03562507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg/dose IV, Day 1 of each 28-day cycle
Study NCT02785705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poliovirus vaccine
Description: Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
Study NCT02152046 — intervention group
Intervention type: PROCEDURE
Intervention: ROP exam with spring loaded retractor
Study NCT00693303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwriting Training using My Scrivener
Description: Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
Study NCT02368236 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Printout
Description: The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
Study NCT02152046 — intervention group
Intervention type: PROCEDURE
Intervention: ROP exam with screw retractor
Study NCT01477476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
Study NCT01477476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A placebo will be given to 7 subjects.
Study NCT00709254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. fentanyl
Description: single dose, 200 ug
Study NCT02200575 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT01369056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Adherence Counseling (AdvAdh)
Description: AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
Study NCT00709254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mL AeroLEF (500 µg/1 mL)
Description: A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
Study NCT00709254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mL AeroLEF (500 µg/1 mL)
Description: A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
Study NCT01056861 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxin A
Description: Not exceeding a total dose of 400 units, once every three months.
Study NCT00460733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate sodium
Description: Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
Study NCT00460733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium & Vitamine D3
Description: 1000 mg of calcium and 400 UI of Vitamine D3
Study NCT01747135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Study NCT00350753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab
Description: Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
Study NCT02525458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QAMS-containing PMMA
Description: Wear retainer with QMAS-containing PMMA on one side of retainer
Study NCT02525458 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QAMS-free PMMA
Description: Wear retainer with QMAS-free PMMA on other side of retainer
Study NCT04033822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
Study NCT03982316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Migraine Management
Description: 1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
Study NCT00517426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
Study NCT03575637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
Study NCT01310868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA
Description: 5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
Study NCT01310868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel wafers
Description: The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
Study NCT01310868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: 60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
Study NCT01310868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
Study NCT01310868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
Study NCT01752413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate 325mg
Description: Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
Study NCT01752413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: All blood donors receive current dietary counseling recommending iron rich foods
Study NCT01752413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: All blood donors receive current dietary counseling recommending iron rich foods
Study NCT03823729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elosan Cabin
Description: The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
Study NCT01713062 — intervention group
Intervention type: DEVICE
Intervention: Vitelene
Description: THA
Study NCT01713062 — intervention group
Intervention type: DEVICE
Intervention: XLPE
Description: THA
Study NCT04201912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: saliva analysis for Toll like receptor activity
Description: Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
Study NCT04201912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: saliva analysis for Toll like receptor activity
Description: Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
Study NCT00653315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol APAP
Description: Tablets, 37.5mg/325mg, single dose
Study NCT00653315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tablets, 37.5mg/325mg
Study NCT01815398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
Study NCT01815398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Skills Training
Description: Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
Study NCT02283944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Pulsed non-invasive brain stimulation using electromagnets
Study NCT03317808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Different exercise
Description: Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
Study NCT03317808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Different exercise
Description: Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
Study NCT02415725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
Study NCT02689700 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
Study NCT06559020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangroo mother care
Description: Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
Study NCT04374773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5 mg PO administered once prior to and once after 1 week of hormone therapy
Study NCT00829530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg
Study NCT00829530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg
Study NCT06561997 — intervention group
Intervention type: DEVICE
Intervention: Robot-assisted
Description: received percutaneous pedicle screw fixation (PPSF) with robotic assistance
Study NCT06561997 — intervention group
Intervention type: DEVICE
Intervention: Free-hand
Description: received percutaneous pedicle screw fixation (PPSF) without robotic assistance
Study NCT00881634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
Study NCT00881634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Study NCT02703194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
Study NCT02703194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
Study NCT03714594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
Study NCT03714594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
Study NCT03714594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg + Dapagliflozin 10 mg
Description: Please see Intervention 1 and 2
Study NCT02226289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab with the latest received cytotoxic regimen
Study NCT04173104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR with [18F]PARPi
Description: One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
Study NCT04173104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PARPi
Description: Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Study NCT02861300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Study NCT02861300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Study NCT00875667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.
Study NCT00875667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigators choice single agent
Description: Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine